Sub-dissociative Dose Ketamine Dosing Study
| Status: | Recruiting |
|---|---|
| Conditions: | Chronic Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | 18 - 59 |
| Updated: | 3/30/2019 |
| Start Date: | October 15, 2018 |
| End Date: | June 15, 2019 |
| Contact: | Shannon Lovett, MD |
| Email: | slovett@lumc.edu |
| Phone: | 708-327-2549 |
A Randomized, Controlled Trial of Intravenous Sub-dissociative Ketamine at Two Doses for Analgesia in the Emergency Department
Goal is to determine if in adults presenting to the Emergency Department (ED) with moderate
to severe acute pain, Ketamine administered at 0.15 mg/kg will provide similar pain relief to
Ketamine administered at 0.3 mg/kg, with fewer adverse effects.
to severe acute pain, Ketamine administered at 0.15 mg/kg will provide similar pain relief to
Ketamine administered at 0.3 mg/kg, with fewer adverse effects.
Study investigators will enroll participants who present to the Emergency Department (ED)
with moderate to severe acute pain, and require intravenous pain medication. Participants
will be double-blinded and randomized to one of the two treatment groups.
Investigators aim to determine if ketamine 0.15 mg/kg IVPB is non-inferior to ketamine 0.3
mg/kg IVBP for the treatment of acute moderate to severe pain in the Emergency Department
(ED). Study investigators hypothesize that in adults presenting to the ED with moderate to
severe acute pain, SDK administered at 0.15 mg/kg will provide similar pain relief to SDK at
0.3 mg/kg, with reduced adverse effects.
with moderate to severe acute pain, and require intravenous pain medication. Participants
will be double-blinded and randomized to one of the two treatment groups.
Investigators aim to determine if ketamine 0.15 mg/kg IVPB is non-inferior to ketamine 0.3
mg/kg IVBP for the treatment of acute moderate to severe pain in the Emergency Department
(ED). Study investigators hypothesize that in adults presenting to the ED with moderate to
severe acute pain, SDK administered at 0.15 mg/kg will provide similar pain relief to SDK at
0.3 mg/kg, with reduced adverse effects.
Inclusion Criteria:
- Adults ages 18-59
- Weight 45 - 115 kg
- Acute abdominal, flank, back, musculoskeletal pain, or a headache
- Onset of pain within 7 days
- Pain score of 5 or more
- Requiring intravenous analgesia
- Hasn't been enrolled in this study previously
Exclusion Criteria:
- Pregnancy
- Breast-feeding
- Altered mental status rendering the patient unable to consent to the study
- Allergy to ketamine
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or
>150 beats/minute, and respiration rate <10 or >30 breaths/minute)
- History of acute head or eye injury, seizure, intracranial hypertension
- Chronic pain
- Renal or hepatic insufficiency
- Known alcohol or drug use disorder
- Currently under influence of alcohol/opiates
- Acute psychiatric illness
We found this trial at
1
site
2160 South 1st Avenue
Maywood, Illinois 60153
Maywood, Illinois 60153
(888) 584-7888
Phone: 847-951-2936
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
Click here to add this to my saved trials
